Global health focus Adjuvant Capital is a life sciences investment firm dedicated to global health with a track record of funding high-burden and neglected disease opportunities, indicating a potential for partnerships around disease prevention, diagnostics, and affordable therapeutics in underserved markets.

Early to growth-stage The firm targets investments in the $10-25 million range across various rounds, suggesting opportunities to engage across multiple financing stages for portfolio companies, from expansion rounds to later-stage pipeline development.

Recent wins Notable recent investments in VitriVax and LimmaTech Biologics show appetite for innovative vaccines and biologics, signaling openness to partnerships in vaccine formulation, manufacturing partnerships, and scale-up capabilities.

Public engagement Active participation in World Bank and IMF meetings and emphasis on bridging global health financing gaps indicate value in connections with development finance, donor networks, and blended finance opportunities.

Operational footprint Small to mid-sized team (11-50 employees) leveraging a strong tech stack and growth-oriented capital suggests a conductor role for venture-backed growth, enabling collaboration on go-to-market strategies, regulatory navigation, and international expansion for portfolio companies.